Nascent Biotech, Inc. (NBIO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Vero Beach, FL, アメリカ. 現CEOは Sean Carrick.
NBIO を有する IPO日 2009-12-03, に上場 Other OTC, 時価総額 $51.67K.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
